IGF-1 LR3

Overview

IGF-1 LR3 (Long Arginine 3-IGF-1) is an 83-amino-acid synthetic analog of the naturally occurring 70-amino-acid human insulin-like growth factor 1. It carries a glutamic-acid-to-arginine substitution at position 3 and a 13-amino-acid N-terminal extension. These modifications sharply reduce its binding affinity for IGF-binding proteins (IGFBPs) — the proteins that normally sequester and inactivate circulating native IGF-1 — resulting in roughly 3-fold greater in vitro potency and a longer reported functional half-life (20–30 hours versus 12–15 hours for native IGF-1).¹

Also known as: Long R3 IGF-1, Long Arginine³-IGF-1. It should never be confused with mecasermin (brand name Increlex), a chemically distinct, FDA-approved recombinant human IGF-1 product used for a narrow pediatric indication.² IGF-1 LR3 has never been developed as, or marketed as, an approved pharmaceutical — it is sold exclusively as a "research chemical," is not listed on any FDA 503A or 503B bulk drug substance category list, and exists entirely outside the legitimate pharmaceutical supply chain.

How it works

IGF-1 LR3 signals primarily through the IGF-1 receptor (IGF-1R), a receptor tyrosine kinase. Ligand binding activates the PI3K/Akt/mTOR signaling cascade, which simultaneously increases protein synthesis via p70S6 kinase activation and decreases protein degradation via suppression of the FOXO1 transcription factor — a "dual anabolic" mechanism that is mechanistically plausible for muscle growth. In vitro, Long R3 IGF-1 at concentrations as low as 10 ng/mL has induced significant myotube hypertrophy in cell culture through this Akt-dependent pathway, with the effect blocked by co-expression of myostatin, a natural growth inhibitor.¹

Here's the critical nuance that underground literature routinely elides: systemic (whole-body) administration behaves very differently from local, cell-culture exposure. Animal studies show that systemic Long R3 IGF-1 infusion suppresses endogenous GH, native IGF-1, and IGFBP-3 through hypothalamic-pituitary negative feedback — meaning injecting this compound into the whole body may actually suppress a person's own natural GH/IGF-1 axis, a very different and potentially counterproductive outcome compared with the high-concentration myotube-hypertrophy effects seen in a petri dish. The reported 20–30 hour half-life reflects this reduced IGFBP affinity, but comes from animal and in vitro modeling — not confirmed human pharmacokinetic studies. In underground bodybuilding practice, it's administered subcutaneously or intramuscularly, sometimes injected locally into a specific trained muscle based on a theory of localized effect that has no controlled human data behind it.

What the research shows

Animal / preclinical evidence

Cell-culture (myotube) studies, referenced in secondary summaries, demonstrate that Long R3 IGF-1 induces myotube hypertrophy via Akt/mTOR signaling at nanomolar concentrations.¹ These are basic-science mechanistic studies in cultured cells, not clinical trials, and cannot establish human safety or efficacy on their own. Separately, animal (systemic infusion) models show that whole-body Long R3 IGF-1 administration suppresses the endogenous GH-IGF-1-IGFBP-3 axis via negative feedback — an important preclinical finding suggesting that systemic use may not simply "add" anabolic signal but could paradoxically down-regulate the body's own axis. No equivalent human study exists to confirm or refute this in people.

Human evidence

There is none for IGF-1 LR3 itself. The closest available human data come from a related but distinct molecule: a review by Handelsman and Heffernan on the use of growth hormone, IGF-1, and insulin for anabolic purposes reports that in a controlled human trial, one year of recombinant IGF-I treatment (15 mcg/kg twice daily, roughly 2,200 mcg/day) failed to improve muscle mass in postmenopausal women — directly undercutting the assumption that IGF-1-axis stimulation reliably produces hypertrophy in humans. The review states plainly that "there is currently no direct in vivo human evidence to suggest IGF-I significantly increases muscle mass."² That same review documents adverse effects associated with rhIGF-1 misuse — hypoglycemia, seizures, jaw pain, myalgia, edema, headaches, and increased liver and kidney mass — and the first documented case of recombinant GH abuse-induced acute renal failure, reported in 2007. Because IGF-1 LR3 acts on the same receptor as native and recombinant IGF-1, these adverse-effect categories are considered relevant by extension, even though IGF-1 LR3 itself has never been studied directly.

Bottom line: No pharmacokinetic, dose-ranging, safety, or efficacy trial of IGF-1 LR3 specifically has ever been published in a peer-reviewed human clinical journal. All dosing protocols circulating in bodybuilding and performance-enhancement communities are derived from anecdotal use and forum-based trial-and-error, extrapolated from native-IGF-1 dosing — not from any validated clinical source. Any human use of this compound is entirely uncontrolled and unsupported by trial-level safety or efficacy data specific to the compound itself.

Typical use and dosing

There is no clinically validated dosing information for IGF-1 LR3. What follows reflects underground bodybuilding and research-chemical vendor literature — not peer-reviewed sources — and is presented purely for educational transparency about what circulates publicly, not as guidance.

None of these patterns have been validated in any controlled human study. They should be understood as informal community practice, not clinical guidance of any kind.

Safety, side effects, and who should avoid it

Because there is no human trial data on IGF-1 LR3 itself, safety information here is extrapolated from the IGF-1 receptor pharmacology it shares with native and recombinant IGF-1, plus case reports and pharmacovigilance concerns about unregulated peptide use generally. Reported associations include increased liver and kidney mass in misuse settings, mechanistically consistent with IGF-1's known mitogenic and growth-promoting activity. IGF-1 signaling is also implicated broadly in cancer-cell proliferation biology; chronic supraphysiologic IGF-1R activation carries a theoretical, unquantified malignancy-promotion risk — a concern shared across the GH/IGF-1 axis literature generally, but amplified here by the complete absence of human safety monitoring data specific to this compound.²

Per animal data, systemic administration may also suppress the body's own GH-IGF-1-IGFBP-3 axis — a counterintuitive risk that underground users are typically unaware of. Additional adverse effects reported in the broader IGF-1 misuse literature include seizures, jaw pain, myalgia, edema, and headache.

Regulatory status

IGF-1 LR3 is not FDA-approved in any form, and is not listed on any FDA 503A or 503B bulk drug substance category list — unlike BPC-157, CJC-1295, and ipamorelin, which were explicitly nominated and categorized. It has never entered the legitimate compounding-pharmacy nomination process at all.⁴ The only FDA-approved recombinant IGF-1 product is mecasermin (Increlex), indicated narrowly for severe primary IGF-1 deficiency or GH gene deletion with GH-neutralizing antibodies — a completely different clinical context from bodybuilding or performance use, and a chemically distinct molecule from IGF-1 LR3.²

No specialty society, medical guideline, or position statement of any kind addresses IGF-1 LR3. Unlike sermorelin, CJC-1295, ipamorelin, and tesamorelin — all at least discussed in the context of general GH-axis guidelines such as AACE/ACE 2019 — IGF-1 LR3 does not appear in any endocrine society guideline, position statement, or consensus document, because it has never been the subject of legitimate clinical development or an FDA New Drug Application.³ The only guideline-adjacent literature touching on IGF-1 pharmacology in an anabolic-misuse context is anti-doping and sports-medicine literature, which discusses IGF-1 axis misuse generally in the context of doping control — not IGF-1 LR3 specifically.

All IGF-1 LR3 in circulation is sold through research-chemical vendors, with no FDA quality oversight and no verified purity or sterility standards. Under WADA's Prohibited List, IGF-1 and IGF-1 analogs — including Long R3 IGF-1 — fall under Section S2 ("Peptide Hormones, Growth Factors, Related Substances, and Mimetics"), prohibited at all times, in and out of competition.⁵

Frequently asked questions